Hospital Profile
Name | Santa Ynez Valley Cottage Hospital |
---|
Type | Critical Access Hospital |
---|
Location | 2050 Viborg Rd, Solvang, California |
---|
Ownership | Voluntary non-profit - Private |
---|
Emergency Services | Yes |
---|
Medicare ID (CCN) | 051331 |
Patients' Experience Survey:
Willingness to Recommend Hospital:
Yes Patients who reported YES, they would definitely recommend the hospital
Probably Patients who reported YES, they would probably recommend the hospital
No Patients who reported NO, they would probably not or definitely not recommend the hospital
Cleanliness of Hospital Environment:
Always Patients who reported that their room and bathroom were "Always" clean
Usually Patients who reported that their room and bathroom were "Usually" clean
Sometimes or Never Patients who reported that their room and bathroom were "Sometimes" or "Never" clean
Quietness of Hospital Environment:
Always Patients who reported that the area around their room was "Always" quiet at night
Usually Patients who reported that the area around their room was "Usually" quiet at night
Sometimes or Never Patients who reported that the area around their room was "Sometimes" or "Never" quiet at night
Always Patients who reported that their nurses "Always" communicated well
Usually Patients who reported that their nurses "Usually" communicated well
Sometimes or Never Patients who reported that their nurses "Sometimes" or "Never" communicated well
Always Patients who reported that their doctors "Always" communicated well
Usually Patients who reported that their doctors "Usually" communicated well
Sometimes or Never Patients who reported that their doctors "Sometimes" or "Never" communicated well
Responsiveness of Hospital Staff:
Always Patients who reported that they "Always" received help as soon as they wanted
Usually Patients who reported that they "Usually" received help as soon as they wanted
Sometimes or Never Patients who reported that they "Sometimes" or "Never" received help as soon as they wanted
Communication about Medicines:
Always Patients who reported that staff "Always" explained about medicines before giving it to them
Usually Patients who reported that staff "Usually" explained about medicines before giving it to them
Sometimes or Never Patients who reported that staff "Sometimes" or "Never" explained about medicines before giving it to them
Yes Patients who reported that YES, they were given information about what to do during their recovery at home
No Patients who reported that NO, they were not given information about what to do during their recovery at home
Always Patients who "Strongly Agree" they understood their care when they left the hospital
Usually Patients who “Agree” they understood their care when they left the hospital
Sometimes or Never Patients who “Disagree” or “Strongly Disagree” they understood their care when they left the hospital
NPI Associated with the Hospital:
Unlike individual providers, Hospitals may have multiple NPI numbers for example, there can be a separate NPI for each unit within the hospital. We have found possible NPI number/s associated with Santa Ynez Valley Cottage Hospital from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.
NPI Number | 1952301863 |
Organization Name | SANTA YNEZ VALLEY COTTAGE HOSPITAL, INC |
Address | 2050 Viborg Rd, Solvang, CA 93463 |
Hospital Type | General Acute Care Hospital |
Phone Number | 805-688-6431 |
News Archive
AACC and Phi Theta Kappa Honor Society announce 2011 recipients of Frank Lanza Memorial Scholarships
The American Association of Community Colleges (AACC) and Phi Theta Kappa Honor Society, with the generous support of Medical Education Technologies, Inc. (METI) and L-3 Communications, Inc., are pleased to announce the 2011 recipients of the Frank Lanza Memorial Scholarships. The scholarships recognize the accomplishments of students enrolled in allied health programs offered by regionally accredited community colleges. Twenty-five students received scholarships of $1,000 each.
Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug
Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.
16% of all new HIV cases reported in Canada linked to immigrants
About 16% of all new HIV cases reported in Canada in 2005 were linked to immigrants from countries where HIV is prevalent, according to a report recently released by the British Columbia Centre for Disease Control, the CP/Toronto Star reports.
Cell research to eventually develop new treatments for cancer and disorders such as Parkinson's and Huntington's disease
Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells die. The work may help scientists to eventually develop new treatments for cancer and disorders such as Parkinson's and Huntington's disease.
Read more Medical News
› Verified 9 days ago
Structural Quality Measures:
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
AACC and Phi Theta Kappa Honor Society announce 2011 recipients of Frank Lanza Memorial Scholarships
The American Association of Community Colleges (AACC) and Phi Theta Kappa Honor Society, with the generous support of Medical Education Technologies, Inc. (METI) and L-3 Communications, Inc., are pleased to announce the 2011 recipients of the Frank Lanza Memorial Scholarships. The scholarships recognize the accomplishments of students enrolled in allied health programs offered by regionally accredited community colleges. Twenty-five students received scholarships of $1,000 each.
Quark Pharmaceuticals announces option agreement with Novartis for QPI-1002 siRNA drug
Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.
16% of all new HIV cases reported in Canada linked to immigrants
About 16% of all new HIV cases reported in Canada in 2005 were linked to immigrants from countries where HIV is prevalent, according to a report recently released by the British Columbia Centre for Disease Control, the CP/Toronto Star reports.
Cell research to eventually develop new treatments for cancer and disorders such as Parkinson's and Huntington's disease
Medical Research Council (MRC) scientists have made an important advance in understanding the biological processes involved when cells die. The work may help scientists to eventually develop new treatments for cancer and disorders such as Parkinson's and Huntington's disease.
Read more News
› Verified 9 days ago